Emerging Pathogens, Vaccine and Breakthrough Infection News and Medical Cases
No significant difference in hospitalization between immunized and non-immunized found for SARS-CoV-2 Beta variant
Get link
Facebook
X
Pinterest
Email
Other Apps
A study of vaccinated and unvaccinated residents of Bangladesh observed that ChAdOx1 could not prevent the new infection or severe COVID-19 disease outcome with single dose when infections were mostly caused by B.1.351 (the Beta) variants of SARS-CoV2.
About 39% (n = 42) of the respondents were infected after the COVID-19 vaccination. The first dose of ChAdOx1 nCoV-19 vaccine was received by 40 (37.0%) cases and both doses were completed by only 2 (2%) cases. The average duration between vaccination (partially or completely immunized) and COVID 19 diagnosis was 32 (±17) days.
The hospitalization rate of comorbid patients was 23.5% among the immunized and 24.1% among the nonimmunized groups. There was no significant difference in duration of hospitalization either (p=0.78).
Genomic analysis of SARS-CoV-2 variants of concern identified from the ChAdOx1 nCoV-19 immunized patients from Southwest part of Bangladesh
Al-Emran HM, Hasan MS, Setu MA, Rahman MS, Alam AR, Sarkar SL, Islam MT, Islam MR, Rahman MM, Islam OK, Jahid IK. Genomic analysis of SARS-CoV-2 variants of concern identified from the ChAdOx1 nCoV-19 immunized patients from Southwest part of Bangladesh. Journal of Infection and Public Health. 2021 Dec 7.
A 25-year-old female developed partial loss of smell 2 days after the injection of the AstraZeneca vaccine (first injection). The taste evaluation was normal. Patient did not take any medication and did not follow olfactory training. She reported that the smell disorder lasted 10 days. Patient did not report adverse event after the second vaccine injection. A 27-year-old female experienced loss of smell after the first injection of the AstraZeneca vaccine. The patient medical history was unremarkable. She perceived an improvement of smell sense 9 days after the vaccine without olfactory training or medical treatment. Patient did not report adverse event after the second vaccine injection. A 51-year-old female developed total loss of smell 2 days after the first injection of AstraZeneca vaccine. She also reported arthralgia, fever, and chills during a few days. The total loss of smell persisted one week with a subsequent progressive improvement of smell. The patient report...
A previously healthy woman in her 60s had mild fever and uneventful course after the 1st dose of ChAdOx1 nCoV-19 vaccine, but developed behavioral problems and refusal to take food, one day after receiving the second dose of ChAdOx1 nCoV-19 vaccination (dose interval 84 days). Her condition progressed rapidly with onset of confusion, forgetfulness, and hallucinations within the next 5 days. Over the next two days, the patient developed difficulty in walking and echolalia. She was prescribed amantadine, trihexyphenidyl and clonazepam by a local practitioner but she showed further deterioration in the form of irritability, incoherent speech, aggravated forgetfulness, auditory and visual hallucinations, abnormal movements of limbs, and jaw and neck dystonia. The patient had a serum anti-Spike protein IgG titer of 1891.5 AU/mL (non-reactive<50 AU/mL) at 37 days post-second dose. An initial magnetic resonance imaging (MRI) of the brain had revealed FLAIR hyperintensity in bila...
Post-Vaccination IgG4 and IgG2 Class Switching is linked to Increased Risk of SARS-CoV-2 Infections A new study published in Infectious Disease Practice has revealed a concerning correlation between the class switching of antibodies after COVID-19 mRNA booster vaccinations and a heightened risk of breakthrough infections. Specifically, the study found that elevated levels of IgG4 and IgG2 antibodies, which increase significantly following the third mRNA dose, are linked to an increased risk of symptomatic SARS-CoV-2 infections. The study followed a longitudinal cohort of 83 healthcare workers who received three vaccine doses, with an additional 66 participants analyzed at a specific timepoint (T9, May 2022), four months after the first booster. Conducted in Spain, the research tracked immune responses over nearly three years, revealing that the proportion of non-cytophilic antibodies (IgG4 and IgG2) increased relative to cytophilic subclasses (IgG1 and IgG3) after the booster. Th...
Comments
Post a Comment